Reindl M - Search Results

1

Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.

Gredler V, Mader S, Schanda K, Hegen H, Di Pauli F, Kuenz B, Deisenhammer F, Berger T, Reindl M, Lutterotti A. Gredler V, et al. Among authors: reindl m. J Neurol Sci. 2013 May 15;328(1-2):77-82. doi: 10.1016/j.jns.2013.02.024. Epub 2013 Mar 21. J Neurol Sci. 2013. PMID: 23522498

2

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Deisenhammer F, et al. Among authors: reindl m. Neurology. 1999 Apr 12;52(6):1239-43. doi: 10.1212/wnl.52.6.1239. Neurology. 1999. PMID: 10214750

3

Increased expression of apolipoprotein D following experimental traumatic brain injury.

Franz G, Reindl M, Patel SC, Beer R, Unterrichter I, Berger T, Schmutzhard E, Poewe W, Kampfl A. Franz G, et al. Among authors: reindl m. J Neurochem. 1999 Oct;73(4):1615-25. doi: 10.1046/j.1471-4159.1999.0731615.x. J Neurochem. 1999. PMID: 10501208 Free article.

4

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T. Reindl M, et al. Brain. 1999 Nov;122 ( Pt 11):2047-56. doi: 10.1093/brain/122.11.2047. Brain. 1999. PMID: 10545390 Clinical Trial.

5

A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells.

Mayringer I, Reindl M, Berger T. Mayringer I, et al. Among authors: reindl m. J Immunol Methods. 2000 Feb 21;235(1-2):33-40. doi: 10.1016/s0022-1759(99)00208-2. J Immunol Methods. 2000. PMID: 10675755

6

A comparative study of the relative bioavailability of different interferon beta preparations.

Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. Deisenhammer F, et al. Among authors: reindl m. Neurology. 2000 Jun 13;54(11):2055-60. doi: 10.1212/wnl.54.11.2055. Neurology. 2000. PMID: 10851362 Clinical Trial.

7

Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.

Berger T, Reindl M. Berger T, et al. Among authors: reindl m. J Neural Transm Suppl. 2000;(60):351-60. doi: 10.1007/978-3-7091-6301-6_25. J Neural Transm Suppl. 2000. PMID: 11205153 Review.

8

Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.

Deisenhammer F, Reindl M, Berger T. Deisenhammer F, et al. Among authors: reindl m. J Interferon Cytokine Res. 2001 Mar;21(3):167-71. doi: 10.1089/107999001750133195. J Interferon Cytokine Res. 2001. PMID: 11331039

9

Increased intrathecal production of apolipoprotein D in multiple sclerosis.

Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F, Berger T. Reindl M, et al. J Neuroimmunol. 2001 Oct 1;119(2):327-32. doi: 10.1016/s0165-5728(01)00378-2. J Neuroimmunol. 2001. PMID: 11585636

10

Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis.

Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Egg R, et al. Among authors: reindl m. Mult Scler. 2001 Oct;7(5):285-9. doi: 10.1177/135245850100700503. Mult Scler. 2001. PMID: 11724443

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

418 results

Search Page

Filters